N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

US9409909B2 · kind B2 · utility

Assignee

• CHEMOCENTRYX, INC. · US

Inventors

• Trevor T. Charvat · San Jose, US
• Cheng Hu · Menlo Park, US
• Anita Melikian · San Francisco, US
• Aaron Novack · San Jose, US
• Andrew Pennell · San Francisco, US
• Edward J. Sullivan · Midland, US
• William D. Thomas · San Jose, US
• Solomon Ungashe · Fremont, US
• Penglie Zhang · Foster City, US
• Jay P. Powers · Pacifica, US
• Sreenivas Punna · Sunnyvale, US

Key dates

• Filing date: Jul 29, 2014
• Grant date: Aug 9, 2016
• Expiry date: Jul 29, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/999
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.